GO
Loading...

Sanofi SA

More

  • SHANGHAI, May 18- Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc could be just the start of the pharmaceutical industry's problems in its biggest emerging drugs market, according to industry sources in China.

  • PARIS, May 15- France's decision to expand its veto powers over strategic sectors to give it some leverage on the future of engineering group Alstom reflects a rare area of policy consensus that resonates across the political spectrum.

  • *Sanofi has restructured R&D, has strong pipeline-Zerhouni. PARIS, May 15- France's Sanofi has strengthened its drug pipeline and has enough future blockbusters lined up for it to steer clear of the M&A frenzy "overheating" the industry, the drugmaker's R&D chief told Reuters.

  • SHANGHAI, May 15- GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be charged with leading a network of corruption in China's pharmaceutical industry, two sources with ties to the businessman and knowledge of the investigation said.

  • SHANGHAI, May 15- GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be charged with leading a network of corruption in China's pharmaceutical industry, two sources with ties to the businessman and knowledge of the investigation said.

  • Midday movers: Aaron's, Eli Lilly, Gogo & More Monday, 12 May 2014 | 12:30 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • May 12- Eli Lilly and Co said its type 2 diabetes drug was more effective than Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in three late-stage trials. Sanofi's Lantus is the world's most prescribed insulin product with quarterly worldwide sales of about $2 billion. The drug will lose U.S. patent protection in February 2015.

  • May 12- Eli Lilly and Co said its type 2 diabetes treatment was as effective as Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in three late-stage trials.

  • Early movers: PF, AZN, PFE, CS, P & more Monday, 12 May 2014 | 7:46 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • May 11- U.S. medical firm Allergan Inc declined to comment on Sunday on a report that it has been seeking offers from rival companies to combat Valeant Pharmaceuticals International's $47 billion cash and share offer.

  • PARIS, May 7- Economy Minister Arnaud Montebourg stepped up France's push for a weaker euro on Wednesday, saying political leaders had the right to assess the right level for the currency in a position completely at odds with Germany's.

  • FACTBOX-M&A frenzy transforming global pharma Tuesday, 6 May 2014 | 2:00 PM ET

    MAY May 6- Merck& Co Inc agrees to sell its consumer care business to Germany's Bayer AG for $14.2 billion. May 2- Pfizer Inc raises its offer for AstraZeneca Plc to 63 billion pounds, but the British company promptly rejects the proposal, which would create the world's biggest pharmaceuticals company.

  • Aspirin and suntan lotion? Bayer, Merck do deal Tuesday, 6 May 2014 | 7:13 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Bayer will acquire the consumer care business of U.S.-based Merck & Co for $14.2 billion in cash, the company said in a statement Tuesday.

  • France's Sanofi and U.S. drugmakers Merck& Co and Abbott Laboratories are exploring selling off their mature drugs that have lost patent protection, Reuters reported this week, citing people familiar with the plans.

  • Bayer nears deal to buy Merck consumer unit -sources Thursday, 1 May 2014 | 3:23 PM ET

    LONDON/ NEW YORK, May 1- German drugmaker Bayer AG is nearing an agreement to buy Merck& Co Inc's consumer healthcare unit, people familiar with the matter said, in a deal that could value the business at around $14 billion.

  • *India welcomes U.S. trade decision. NEW DELHI, May 1- India said on Thursday it would hold trade talks on intellectual property rights with the United States after its general election, buying time to address friction over drug patents until a new government is formed.

  • Merck explores $15 billion drug portfolio sale: Sources Wednesday, 30 Apr 2014 | 10:20 PM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter.

  • NEW YORK/ LONDON, April 30- Merck& Co Inc is considering selling a big portfolio of mature drugs that could fetch more than $15 billion, according to people familiar with the matter, as the U.S. drugmaker continues to streamline businesses to focus on high-growth areas.

  • After-hours buzz: Allergan, MetLife, Yelp & more Wednesday, 30 Apr 2014 | 5:00 PM ET

    Headlines after the bell Wednesday: Allergan, MetLife, Yelp

  • *Alstom jumps; among most shorted stocks on Paris bourse. Alstom jumped 9.3 percent after saying it would review a binding offer from General Electric for its energy business by the end of May and left the door open for a competing bid from Germany's Siemens.